Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Arq. neuropsiquiatr ; 57(2A): 284-7, jun. 1999. ilus
Article in English | LILACS | ID: lil-234464

ABSTRACT

Human T-cell lumphotropic virus type I (HTLV-I) associated myelopathy / tropical spastic paraparesis (HAM/TSP) is the most common chronic myelopathy in Brazil. We present the case of a 53 year old man that fulfiled the diagnostic criteria for HAM/TSP but had at the magnetic resonance imaging (MRI) of the spinal cord evidences of syringohydromyelia at the C6-C7 and D2-D7 levels along with Chiari type I malformation. The clinical picture was more typical of HAM/TSP than of syringohydromyelia, which was probably asymptomatic. The present case clearly demonstrates that sorology and neuroimaging should be always use together. We conclude that, specially in places where HTLV-I is endemic, every patient with a spatic paraparesis, even with a radiological picture suggestive of a structural spinal cord lesion, should have a screening test for HTLV-I. The clinical picture must dictate the final direction of the diagnosis.


Subject(s)
Middle Aged , Humans , Male , Paraparesis, Tropical Spastic/diagnosis , Syringomyelia/diagnosis , Magnetic Resonance Imaging , Paraparesis, Tropical Spastic/complications , Spinal Cord/pathology , Syringomyelia/complications
2.
Rev. bras. neurol ; 33(2): 72-7, mar.-abr. 1997. tab
Article in Portuguese | LILACS | ID: lil-190994

ABSTRACT

Esta revisão sumária sobre terapêutica em epilepsia aborda questões tais como quando começar o tratamento, qual a droga antiepilética (DAE) indicada para os diversos tipos de crise, quando retirar a DAE, sua posologia, frequência de tomadas, efeitos colaterais e idução/inibição enzimática da DAE, monitorização do tratamento e epilepsia refratária. Várias dessas questões são dependentes do conhecimento de farmacocinética e farmacodinâmica, fatos que também são considerados.


Subject(s)
Valproic Acid/adverse effects , Valproic Acid/pharmacokinetics , Valproic Acid/pharmacology , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/pharmacokinetics , Anti-Anxiety Agents/pharmacology , Anticonvulsants/pharmacokinetics , Anticonvulsants/pharmacology , Epilepsy/drug therapy , Phenytoin/adverse effects , Phenytoin/pharmacokinetics , Phenytoin/pharmacology , Phenobarbital/adverse effects , Phenobarbital/pharmacokinetics , Phenobarbital/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL